Regulatory Compliance - Compliance with HIPAA and HITECH regulations is mandatory, requiring business associates to meet specific privacy and security standards [86]. - The company must comply with corporate practice of medicine laws, which may affect its operational structure and relationships with healthcare providers [99]. - The company is subject to federal and state laws regarding the submission of claims, with potential liabilities for violations [92]. - The company is subject to various healthcare-related regulations that differ by state, impacting operational practices [95]. - The company must maintain a risk management framework and file self-assessment reports with state insurance regulators [93]. - State insurance holding company regulations may restrict the ability to pay dividends and require prior approval for acquisitions [94]. Market Operations - The company's Medicare Advantage plans are rated between 1.0 and 5.0 Stars by CMS, impacting market image and enrollment opportunities [83]. - The company operates in 45 states and the District of Columbia, with its HMO licensed in New Jersey and Texas [93]. - The company has operations in Hong Kong and Canada, subject to local regulations and U.S. laws governing international business conduct [102]. Financial Risks - The False Claims Act allows for treble damages and civil penalties for false claims, which could significantly impact the company's financials [92]. - The primary market risk faced by the company is interest rate risk associated with investments in fixed maturity instruments [357]. - The company manages credit risk by investing in high-quality securities and diversifying its holdings [358]. - As of December 31, 2024, none of the company's fixed maturity securities portfolio was unrated or rated below investment grade [359]. - The company continues to monitor inflation impacts, which may affect operating expenses as a percentage of total revenues if CMS payments do not increase accordingly [360]. Communication Practices - The company routinely announces material information through SEC filings, press releases, public conference calls, and social media channels [104].

Core Insights - Clover Health Investments, Corp. reported a narrower loss per share of 4 cents for Q4 2024, compared to a loss of 14 cents in the same period last year, beating the Zacks Consensus Estimate of a loss of 7 cents [1] - The company’s total revenues for Q4 2024 were $337 million, reflecting a year-over-year increase of 7.9%, although it fell short of the Zacks Consensus Estimate by 2% [2] - For the full year 2024, Clover Health's revenues rose 8.8% year-over-year to $1.34 billion, with a loss per share of 9 cents compared to a loss of 44 cents in the previous year [3] Revenue Breakdown - Insurance revenues in Q4 2024 reached $330.7 million, up 9.1% year-over-year, driven by strong member retention and cohort management [4] - The Insurance Benefits Expense Ratio (BER) was 82.8%, a contraction of 460 basis points year-over-year, while the Medical Care Ratio (MCR) was 73.5%, contracting 890 basis points year-over-year [5] - Other income generated revenues of $6.3 million, down 32.5% year-over-year [5] Operational Performance - Net medical claims decreased by 2.7% year-over-year to $243 million, while salaries and benefits expenses decreased by 3.7% to $62.7 million [6] - General and administrative expenses rose by 22.4% to $52.3 million, leading to total operating expenses of $358.4 million, which declined by 4.6% year-over-year [6] - The total operating loss was $21.4 million, significantly improved from an adjusted operating loss of $63.1 million in the prior-year quarter [6] Financial Position - Clover Health ended Q4 2024 with cash and cash equivalents of $194.5 million, down from $289.7 million at the end of Q3 2024 [7] - Cumulative net cash provided by operating activities from continuing operations was $34.8 million, compared to a net cash used of $144.7 million a year ago [7] Future Guidance - For 2025, Clover Health estimates Insurance revenues to be between $1.8 billion and $1.875 billion, indicating a potential 37% year-over-year growth at the midpoint [9] - The company expects the Insurance BER to be in the range of 87-88%, with average Medicare Advantage membership projected between 103,000 and 107,000, suggesting a 30% year-over-year growth at the midpoint [9] Strategic Developments - Clover Health reported a 27% year-over-year increase in Medicare Advantage membership and a 95% retention rate, indicating competitive advantages and improved star ratings [12] - The company plans to expand services and integrate Clover Assistant to enhance outcomes and cost control [12] - The launch of Counterpart Health, a software division, is expected to provide high-margin SaaS revenues, with initial external partnerships already signed [13]

Financial Data and Key Metrics Changes - Clover Health achieved full-year adjusted EBITDA profitability in 2024, with a significant improvement of $112 million compared to 2023, resulting in over $70 million of adjusted EBITDA [32][33] - Insurance revenue grew by 9% in both Q4 and full-year 2024, reaching $331 million and $1,345 million respectively [25][26] - The insurance benefit expense ratio (BER) improved to 82.8% in Q4 2024 from 87.4% in Q4 2023, while the medical care ratio (MCR) improved to 73.5% from 82.4% year-over-year [25][26] Business Line Data and Key Metrics Changes - Medicare Advantage membership surpassed 100,000 members, reflecting a 27% year-over-year growth and a 95% retention rate during the Annual Enrollment Period (AEP) [8][9] - The launch of Counterpart Health, a software business, has begun to show promise with a growing pipeline of external partners [12][20] Market Data and Key Metrics Changes - The company reported a strong performance in established core markets, which contributed to the majority of new member growth during AEP [41] - The Medicare Advantage switchers from other plans provided more health data, enhancing the ability to manage care effectively [42] Company Strategy and Development Direction - Clover Health aims to expand its technology-driven care management model, focusing on proactive care and chronic disease management [14][16] - The company plans to scale home care services to engage high-risk members and improve health outcomes [19][72] - Counterpart Health is positioned for growth, with a focus on expanding its reach and partnerships in 2025 [50][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining adjusted EBITDA profitability while investing in new member growth and technology enhancements [21][36] - The company anticipates a strong membership growth of 30% year-over-year in 2025, with a focus on improving unit economics for new members [35][44] Other Important Information - Clover Health ended Q4 2024 with $438 million in cash and investments, indicating a strong balance sheet position [33][34] - The company expects adjusted SG&A expenses to be between $355 million and $365 million in 2025, reflecting a 200 basis point improvement year-over-year [36][49] Q&A Session Summary Question: When can revenue metrics from Counterpart Health be expected in financials? - Management indicated that while there is a strong pipeline for Counterpart, it is still early, and financial results will be incorporated later as the business expands [60][62] Question: How much of the G&A load is related to AEP growth, and what are the expectations for 2026? - Management noted that growth SG&A is a significant portion of the increase, but they expect a lower rate of increase moving into 2026 due to ongoing optimization efforts [65][66] Question: Expectations for growth in the home care arm in 2025 and beyond? - Management highlighted home care as a critical part of their strategy, planning to invest more in this area and expand its capabilities [72]

Group 1 - Clover Health Investments, Corp. reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07 per share, and showing improvement from a loss of $0.12 per share a year ago, resulting in an earnings surprise of 128.57% [1] - The company posted revenues of $336.96 million for the quarter ended December 2024, which was 2.02% below the Zacks Consensus Estimate, and a decrease from year-ago revenues of $510.25 million [2] - Clover Health Investments has surpassed consensus EPS estimates in all four of the last quarters, while topping consensus revenue estimates two times during the same period [2] Group 2 - The stock has increased approximately 37.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors to assess future stock performance [4] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $389.7 million, and -$0.07 on revenues of $1.53 billion for the current fiscal year [7] Group 3 - The Medical Info Systems industry, to which Clover Health Investments belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Clover Health Investments is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Fourth Quarter & Full-Year 2024 Earnings Conference Call February 27, 2025 LGTMs: Date: Andrew T. LGTM via email 2/26/25 Peter K. LGTM 2/26/25 Legal (Karen / Peter R.) 2/26/25 Accounting (#s review) 2/25/2025 Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net i ...

Financial Performance - Full year 2024 GAAP Net loss from continuing operations improved by $164 million year-over-year, totaling a loss of $46 million[1] - Full year 2024 Adjusted EBITDA reached $70 million, an increase of $112 million year-over-year[1] - Total revenues for FY 2024 were $1.371 billion, an 8.8% increase from FY 2023[4] - Clover Health reported total revenues of $336.963 million for Q4 2024, a 7.4% increase from $312.385 million in Q4 2023[19] - Premiums earned, net for the year ended December 31, 2024, reached $1.344881 billion, compared to $1.235769 billion in 2023, reflecting an increase of 8.8%[19] - For the year ended December 31, 2024, Clover Health reported a net loss of $43,009 thousand, a significant improvement compared to a net loss of $213,361 thousand in 2023[21] - Adjusted EBITDA for the year ended December 31, 2024, was $70,091 thousand, compared to a loss of $41,555 thousand in 2023[27] - Total revenues for the year 2024 were $1,371,131 thousand, an increase from $1,260,543 thousand in 2023[25] Insurance Revenue and Membership Growth - Insurance revenue for Q4 2024 grew by 9% year-over-year to $331 million, and for the full year 2024, it reached $1.3 billion, also a 9% increase[2] - For full-year 2025, the company projects insurance revenue between $1.800 billion and $1.875 billion, representing a 37% growth year-over-year at the midpoint[6] - Average Medicare Advantage membership increased by 30% year-over-year, reaching between 103,000 and 107,000 for 2025[3] Expense Ratios and Claims - Insurance Benefits Expense Ratio (BER) improved to 82.8% in Q4 2024, down from 87.4% in Q4 2023[4] - The insurance benefits expense ratio (BER) for the year 2024 was 81.2%, an improvement from 86.5% in 2023[31] - The company incurred net medical claims of $243.044 million in Q4 2024, a slight decrease from $249.754 million in Q4 2023[19] - The insurance segment net loss for the year 2024 was $66,513 thousand, a reduction from a net loss of $199,508 thousand in 2023[23] Cash and Assets - Cash, cash equivalents, and investments totaled $437.6 million, a 4.9% increase from the previous year[4] - Clover Health's cash and cash equivalents increased to $194.543 million in 2024 from $116.407 million in 2023, representing a growth of 67%[17] - Clover Health's total assets increased to $580.742 million as of December 31, 2024, up from $570.671 million in 2023[17] - The total liabilities decreased to $239.599 million in 2024 from $284.277 million in 2023, indicating a reduction of approximately 15.7%[17] - Cash and cash equivalents at the end of the period increased to $194,543 thousand from $176,494 thousand at the end of 2023[21] - Net cash provided by operating activities from continuing operations for the year 2024 was $82,450 thousand, a turnaround from a cash used of $35,148 thousand in 2023[21] Company Strategy and Technology - The company plans to maintain strong profitability while investing in membership growth and Clover Assistant technology[2] - Clover Health's focus on technology, particularly the Clover Assistant platform, aims to enhance patient outcomes and reduce healthcare costs[14] Stock-Based Compensation - Stock-based compensation for the year 2024 was $114,331 thousand, down from $140,931 thousand in 2023[25] Definitions and Metrics - Adjusted EBITDA is defined as net loss from continuing operations before various expenses, providing a key measure for evaluating operating performance and trends[34] - Adjusted Net income (loss) from continuing operations excludes stock-based compensation and other non-recurring expenses, aiding in the assessment of financial performance[35] - Insurance Benefits Expense Ratio (BER) is calculated by dividing total insurance net medical expenses and quality improvements by premiums earned, offering insights into healthcare quality investments[36]

Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion ...

Company Overview - Clover Health Investments, Corp. is a physician enablement technology company focused on providing access to quality healthcare for Medicare recipients, particularly seniors who have historically faced challenges in accessing affordable healthcare [1] - The company's strategy is driven by its software platform, Clover Assistant, which aggregates patient data to support clinical decision-making and improve health outcomes through early identification and management of chronic diseases [1] Product and Services - Clover Health offers PPO and HMO Medicare Advantage plans across several states, with a particular emphasis on its flagship wide-network, high-choice PPO plans [1] - The company extends its data-driven technology platform to healthcare providers outside its Medicare Advantage plan through its subsidiary, Counterpart Health, aiming to enhance patient outcomes and reduce healthcare costs nationwide [1] Impact and Performance - Clover Health has published data showcasing the positive impact of its technology on Medication Adherence and the early identification and management of Diabetes and Chronic Kidney Disease [1] Investor Engagement - CFO Peter Kuipers will participate in the 2025 Jefferies Value-Based Healthcare Summit on March 10, 2025, and present at the 2025 Leerink Global Healthcare Conference on March 11, 2025 [2]

WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on February 27, 2025, to discuss Clover Health’s fourth quarter and full year 2024 business and financial results. Fourth Quarter and Full Year 2024 Conference Call and Webcast ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...